GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ningbo Menovo Pharmaceutical Co Ltd (SHSE:603538) » Definitions » Research & Development

Ningbo Menovo Pharmaceutical Co (SHSE:603538) Research & Development : ¥99 Mil (TTM As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Ningbo Menovo Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Ningbo Menovo Pharmaceutical Co's Research & Development for the three months ended in Mar. 2025 was ¥15 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ¥99 Mil.


Ningbo Menovo Pharmaceutical Co Research & Development Historical Data

The historical data trend for Ningbo Menovo Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ningbo Menovo Pharmaceutical Co Research & Development Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.73 88.31 98.16 95.30 99.65

Ningbo Menovo Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.83 26.54 22.11 35.18 15.01

Ningbo Menovo Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Ningbo Menovo Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Ningbo Menovo Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Ningbo Menovo Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
Executives
Xu Jian senior management
Cao Qian Director
Yao Fang Director
Ying Gao Feng Director
Sun Yan Director
Shi Jian Xiang Director
Wu Feng Yun Director
Tu Ying Director
Yao Cheng Zhi Director
Zheng Hui Lin Supervisors
Jiao Hua senior management

Ningbo Menovo Pharmaceutical Co Headlines

No Headlines